What is ctDNA testing and should Inflammatory Breast Cancer patients get it

Understanding ctDNA Testing for Inflammatory Breast Cancer

What is ctDNA Testing?

ctDNA stands for circulating tumor DNA — essentially, pieces of DNA from cancer cells that are floating in your bloodstream. Think of it as a "liquid biopsy" — instead of taking a tissue sample through surgery or biopsy, doctors can detect cancer DNA directly from a blood draw.

How It Works:

When cancer cells die or break apart, they release fragments of their DNA into the bloodstream. Advanced laboratory tests can detect and analyze these fragments to:

• Identify specific mutations (genetic changes) in your cancer
• Track how your cancer is responding to treatment
• Detect early signs of cancer recurrence before imaging shows anything

---

ctDNA Testing for Inflammatory Breast Cancer (IBC)

Current Recommendations:

According to the NCCN Guidelines for Patients: Inflammatory Breast Cancer (2025), ctDNA testing is recognized as part of your biomarker testing options. The guidelines specifically note that:

"Some abnormal changes (mutations) can be found by testing circulating tumor DNA (ctDNA) in the blood. In a liquid biopsy, a sample of blood is taken to look for cancer cells or for pieces of DNA from tumor cells. Sometimes, testing can quickly use up a tumor sample and a liquid biopsy might be an option in this case."

Key point: ctDNA testing may be particularly useful for IBC patients when:

• Your initial tumor tissue sample is limited or has been used up by other testing
• You need quick results to guide treatment decisions
• Your doctor wants to monitor your response to therapy over time

---

Important Limitations to Understand:

According to NCCN Guidelines for Non-Small Cell Lung Cancer (which provides broader guidance on ctDNA use), there are important caveats:

1. ctDNA should NOT replace tissue testing — Tissue biopsy remains the gold standard for initial diagnosis and biomarker testing
2. False negatives are possible — ctDNA tests can miss mutations that are present in your tumor
3. Clonal hematopoiesis interference — Sometimes mutations detected in blood come from normal blood cells, not cancer cells, which can create confusion
4. Low tumor fraction concerns — If there's very little cancer DNA in your blood, results may be unreliable

---

Treatment Response Monitoring with ctDNA:

For IBC patients undergoing treatment, ctDNA can be valuable for monitoring how well treatment is working. According to the medical literature, several ctDNA-based tests are now available:

• Guardant360 Response — Can detect treatment response approximately 8 weeks earlier than standard imaging
• Signatera — Tracks minimal residual disease (MRD) — meaning leftover cancer cells after treatment
• Caris Assure — Provides comprehensive tumor profiling from blood

These tests can help your oncologist understand whether your current treatment is working before imaging studies show changes.

---

Questions to Ask Your IBC Care Team:

1. "Should I have ctDNA testing as part of my initial biomarker workup, or is tissue testing sufficient?"
2. "If my tumor tissue sample is limited, would ctDNA testing help identify treatment options?"
3. "Would ctDNA monitoring during treatment help track my response and guide any treatment adjustments?"
4. "What are the limitations of ctDNA testing in my specific situation?"
5. "If ctDNA testing is done, how will you interpret results, especially regarding potential false positives or negatives?"

---

Bottom Line:

ctDNA testing is a useful complementary tool for IBC patients, particularly for:

• Identifying mutations when tissue is limited
• Monitoring treatment response during therapy
• Detecting early recurrence

However, it works best alongside tissue-based testing, not as a replacement. Your oncologist will determine whether ctDNA testing is appropriate for your individual case based on your specific situation, available tissue samples, and treatment plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.